Matthew R. Dunn

Matthew R. Dunn

Auto-generated profile, based on publicly available information

Matthew R. Dunn

Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SHSandra C Hayes
Sandra C Hayes
MDMatthew Dunn
Matthew Dunn
MPMelanie Louise Plinsinga
Melanie Louise Plinsinga
HRHildegard Reul-Hirche
Hildegard Reul-Hirche
YRYumeng Ren
Yumeng Ren
MTMelissa A. Troester
Melissa A. Troester
The objectives of this work were to (i) describe upper-body symptoms post-breast cancer; (ii) explore the relationship between symptoms and upper-body function, breast cancer-related lymphoedema (BCRL), physical activity levels, and quality of life; and (iii) determine whether the presence of upper-body symptoms predicts BCRL. Nine symptoms, upper-body function, lymphoedema, physical activity, and quality of life were assessed in women with invasive breast cancer at baseline (2- to 9-months post-diagnosis; n = 2442), and at 2- and 7-years post-diagnosis. Mann–Whitney tests, unpaired t-tests, and chi-squared analyses were used to assess cross-sectional relationships, while regression analyses were used to assess the predictive relationships between symptoms at baseline, and BCRL at 2- and 7-years post-diagnosis. Symptoms are common post-breast cancer and persist at 2- and 7-years post-diagnosis. Approximately two in three women, and one in three women, reported >2 symptoms of at least mild severity, and of at least moderate severity, respectively. The presence of symptoms is associated with poorer upper-body function, and lower physical activity levels and quality of life. One or more symptoms of at least moderate severity increases the odds of developing BCRL by 2- and 7-years post-diagnosis (p < 0.05). Consequently, improved monitoring and management of symptoms following breast cancer have the potential to improve health outcomes.

25 January 2024 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
SASarah C. Van Alsten
Sarah C. Van Alsten
MDMatthew R. Dunn
Matthew R. Dunn
AHAlina M. Hamilton
Alina M. Hamilton
JIJoannie M. Ivory
Joannie M. Ivory
XGXiaohua Gao
Xiaohua Gao
MTMelissa A. Troester
Melissa A. Troester
Background: OncotypeDx is a prognostic and predictive genomic assay used in early-stage hormone receptor–positive, HER2− (HR+/HER2−) breast cancer. It is used to inform adjuvant chemotherapy decisions, but not all eligible women receive testing. We aimed to assess variation in testing by demographics and geography, and to determine whether testing was associated with chemotherapy. Methods: For 1,615 women in the Carolina Breast Cancer Study with HR+/HER2−, Stage I–II tumors, we estimated prevalence differences (PD) and 95% confidence intervals (CI) for receipt of OncotypeDx genomic testing in association with and sociodemographic characteristics. We assessed associations between testing and chemotherapy receipt overall and by race. Finally, we calculated the proportion of eligible women receiving OncotypeDx by county-level rurality, census tract-level socioeconomic status, and Area Health Education Center regions. Results: 38% (N = 609) of potentially eligible women were tested, with lower testing prevalences in Black (31%; PD, −11%; 95% CI, −16%–6%) and low-income women (24%; PD, −20%; 95% CI, −29% to −11%) relative to non-Black and higher income women. Urban participants were less likely to be tested than rural participants, though this association varied by region. Among women with low genomic risk tumors, tested participants were 29% less likely to receive chemotherapy than untested participants (95% CI, −40% to −17%). Racial differences in chemotherapy were restricted to untested women. Conclusions: Both individual and area-level socioeconomics predict likelihood of OncotypeDx testing. Impact: Variable adoption of OncotypeDx by socioeconomics and across geographic settings may contribute to excess chemotherapy among patients with HR+/HER2− cancers. See related In the Spotlight, p. 635

1 June 2021 in Preventive Medicine Reports
Verified
Journal Article
Open access
MDMatthew R. Dunn
Matthew R. Dunn
MDMelissa DeJonckheere
Melissa DeJonckheere
SSSam Schuiteman
Sam Schuiteman
ASArianna Strome
Arianna Strome
KHKelsey Herbert
Kelsey Herbert
TCTammy Chang
Tammy Chang
Social distancing is an important public health recommendation that has been implemented to reduce the spread of COVID-19. Infections are rising among younger populations, but relatively little is known about youth social distancing behavior. Our qualitative study aims to examine youth engagement with social distancing and elucidate the reasons why guidelines are followed and broken. Members of the national MyVoice Text Message Cohort (aged 14–24) were surveyed from April 24 to April 30, 2020, through an open-ended text message poll. Responses were inductively coded and analyzed with descriptive statistics. Of the 944 youth who responded (response rate = 81.2%), 95% self-reported social distancing. However, 62% recalled instances of themselves or others breaking the guidelines and 19% expressed misconceptions about the rules. Notably, 14% of youth said they would encourage their friends to social distance by telling them it will accelerate a return to normal life. Feelings of social isolation were the most frequently cited (55%) negative impact of social distancing. Overall, responses from youth indicate significant variation in the interpretation of social distancing guidelines. Public health communications may need to address several critical misconceptions which impact the social distancing behaviors of youth. Further, safe methods for youth to interact with peers during periods of social distancing are necessary to prevent mental health impacts and to ensure adherence to social distancing guidelines.

13 January 2024 in Cancer Causes & Control
Verified
Journal Article
Closed access
PDF file
MDMatthew R. Dunn
Matthew R. Dunn
EMEman M. Metwally
Eman M. Metwally
SVSanah Vohra
Sanah Vohra
THTerry Hyslop
Terry Hyslop
LHLouise M. Henderson
Louise M. Henderson
EBEboneé N. Butler
Eboneé N. Butler

2 December 2024 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MDMatthew R Dunn
Matthew R Dunn
DLDidong Li
Didong Li
MEMarc A Emerson
Marc A Emerson
CTCaroline A Thompson
Caroline A Thompson
HNHazel B Nichols
Hazel B Nichols
MTMelissa A Troester
Melissa A Troester
Background: Delays in breast cancer diagnosis and treatment lead to worse survival and quality of life. Racial disparities in care timeliness have been reported, but few studies have examined access at multiple points along the care continuum (diagnosis, treatment initiation, treatment duration, and genomic testing). Methods and findings: The Carolina Breast Cancer Study (CBCS) Phase 3 is a population-based, case-only cohort (n = 2,998, 50% black) of patients with invasive breast cancer diagnoses (2008 to 2013). We used latent class analysis (LCA) to group participants based on patterns of factors within 3 separate domains: socioeconomic status (“SES”), “care barriers,” and “care use.” These classes were evaluated in association with delayed diagnosis (approximated with stages III–IV at diagnosis), delayed treatment initiation (more than 30 days between diagnosis and first treatment), prolonged treatment duration (time between first and last treatment–by treatment modality), and receipt of OncotypeDx genomic testing (evaluated among patients with early stage, ER+ (estrogen receptor-positive), HER2- (human epidermal growth factor receptor 2-negative) disease). Associations were evaluated using adjusted linear-risk regression to estimate relative frequency differences (RFDs) with 95% confidence intervals (CIs). Delayed diagnosis models were adjusted for age; delayed and prolonged treatment models were adjusted for age and tumor size, stage, and grade at diagnosis; and OncotypeDx models were adjusted for age and tumor size and grade. Overall, 18% of CBCS participants had late stage/delayed diagnosis, 35% had delayed treatment initiation, 48% had prolonged treatment duration, and 62% were not OncotypeDx tested. Black women had higher prevalence for each outcome. We identified 3 latent classes for SES (“high SES,” “moderate SES,” and “low SES”), 2 classes for care barriers (“few barriers,” “more barriers”), and 5 classes for care use (“short travel/high preventive care,” “short travel/low preventive care,” “medium travel,” “variable travel,” and “long travel”) in which travel is defined by estimated road driving time. Low SES and more barriers to care were associated with greater frequency of delayed diagnosis (RFDadj = 5.5%, 95% CI [2.4, 8.5]; RFDadj = 6.7%, 95% CI [2.8,10.7], respectively) and prolonged treatment (RFDadj = 9.7%, 95% CI [4.8 to 14.6]; RFDadj = 7.3%, 95% CI [2.4 to 12.2], respectively). Variable travel (short travel to diagnosis but long travel to surgery) was associated with delayed treatment in the entire study population (RFDadj = 10.7%, 95% CI [2.7 to 18.8]) compared to the short travel, high use referent group. Long travel to both diagnosis and surgery was associated with delayed treatment only among black women. The main limitations of this work were inability to make inferences about causal effects of individual variables that formed the latent classes, reliance on self-reported socioeconomic and healthcare history information, and generalizability outside of North Carolina, United States of America. Conclusions: Black patients face more frequent delays throughout the care continuum, likely stemming from different types of access barriers at key junctures. Improving breast cancer care access will require intervention on multiple aspects of SES and healthcare access.

1 November 2026 in JCO Oncology Practice
Verified
Journal Article
Closed access
IFIlona Fridman
Ilona Fridman
CNChristine Neslund-Dudas
Christine Neslund-Dudas
LBLauren Jordan Barrow
Lauren Jordan Barrow
MDMatthew R. Dunn
Matthew R. Dunn
RJRegina Jones
Regina Jones
JLJennifer A. Elston Lafata
Jennifer A. Elston Lafata
PURPOSE: Telemedicine offers significant benefits, but concerns regarding care quality persist. To inform future oncology telehealth policy, we compared subsequent health care use, patient-reported care quality, and communication outcomes between telehealth and in-person visits. METHODS: An observational cohort study (April 2022-October 2023) included patients age 21+ years with malignant neoplasms, a scheduled oncology visit, and cancer treatment initiated 6 months to 3 years before the study. Black adults and those with telehealth visits were oversampled. Pre- and post-visit telephone survey data were joined with electronic health record data and geocoded community characteristics. Outcomes included subsequent acute care events (emergency department visits and unplanned hospitalizations), follow-up visits, patient perceptions of whether their care needs were met, and communication quality via validated instruments, with Likert-scale responses. We estimated prevalence differences (PDs) in outcomes by visit type using propensity score–weighted generalized linear models that adjusted for patient socioeconomic, health, and census tract–level differences. RESULTS: After propensity score adjustments achieved covariate balance, 487 respondents (93 telehealth, 394 in-person) were included. Mean age was 64 (standard deviation = 13) years; 62% were female, 26% were Black, 82% had some college degree or more, and 25% reported fair/poor health. Follow-up in-person visits at 30 days were more frequent after telehealth (64%, 46%; PD = 0.18 [95% CI, 0.07 to 0.28]), with no differences at 7 or 14 days. Acute care use did not significantly differ at any time point. Quality and communication ratings were similar (PD range: 0.00-0.09), except for perceived privacy: 80% in-person, 67% telehealth, P < .01. CONCLUSION: Although mostly similar health care use and patient perceptions suggest telehealth as a viable oncology option, identified differences highlight the need to ensure privacy and evaluate when telehealth visits are most appropriate.